PRESS RELEASE published on 09/17/2025 at 07:30, 6 months ago Inside Information / Information on annual revenues MaaT Pharma presents positive Half Year 2025 Results with promising data from Phase 3 trial of MaaT013 in aGvHD. Company strengthens position with partnerships and financing Partnerships Phase 3 Trial Half Year Results MaaT Pharma AGvHD
BRIEF published on 07/28/2025 at 07:35, 7 months 20 days ago MaaT Pharma Secures €37.5 Million Loan to Boost Hemato-Oncology Programs Clinical Development EIB Loan Hemato-oncology Microbiome Therapy Xervyteg® Approval
PRESS RELEASE published on 07/28/2025 at 07:30, 7 months 20 days ago Inside Information / Other news releases MaaT Pharma secures €37.5 million loan from the European Investment Bank to advance clinical programs in Hemato-Oncology. Funding supports late-stage assets Xervyteg® and MaaT033 European Investment Bank Clinical Programs Loan MaaT Pharma Hemato-oncology
BRIEF published on 06/24/2025 at 20:05, 8 months 23 days ago MaaT Pharma General Meeting: Results and Appointments Kepler Cheuvreux Resolutions General Assembly MaaT Pharma Appointment Of President
PRESS RELEASE published on 06/24/2025 at 20:00, 8 months 23 days ago Inside Information / Other news releases MaaT Pharma presents Annual General Meeting results, with shareholders approving most resolutions. Jean-Marie Lefevre appointed Chairman. Liquidity contract with Kepler Cheuvreux maintained Annual General Meeting Shareholders Liquidity Contract MaaT Pharma Jean-Marie Lefevre
BRIEF published on 06/19/2025 at 19:05, 8 months 28 days ago MaaT Pharma Advances Xervyteg® Commercialization Efforts European Market Clinical Trials Oncology Microbiome Xervyteg®
PRESS RELEASE published on 06/19/2025 at 19:00, 8 months 28 days ago Inside Information / Other news releases MaaT Pharma provides business update & highlights key milestones for 2025, including MA application submission for Xervyteg, strategic focus in Europe & US trial launch Business Update Clinical-stage Biotechnology MaaT Pharma Key Milestones Xervyteg
BRIEF published on 06/13/2025 at 07:35, 9 months 4 days ago MaaT Pharma Reveals Promising Data for Xervyteg® at EHA Congress Clinical Efficacy Safety Profile Xervyteg® AGvHD EMA Application
PRESS RELEASE published on 06/13/2025 at 07:30, 9 months 4 days ago Inside Information / Other news releases MaaT Pharma presents updated positive data for Xervyteg® in treating acute Graft-versus-Host Disease at EHA Congress, validating high efficacy observed in pivotal ARES study MaaT Pharma Acute Graft-versus-Host Disease EMA Approval Xervyteg EAP Data
BRIEF published on 05/12/2025 at 07:35, 10 months 5 days ago Promising data for MaaT033 in ALS Microbiome Amyotrophic Lateral Sclerosis MaaT033 Safety And Tolerability Phase 1b Clinical Trial
Published on 03/17/2026 at 13:30, 6 hours 40 minutes ago Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 13:30, 6 hours 40 minutes ago Namibia Critical Metals Welcomes Toyota Tsusho as Strategic Partner in the Lofdal Heavy Rare Earths Project
Published on 03/17/2026 at 13:00, 7 hours 10 minutes ago Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Published on 03/17/2026 at 13:00, 7 hours 10 minutes ago High-Resolution Airborne Survey Completed at Music Valley HREE Project
Published on 03/17/2026 at 12:30, 7 hours 40 minutes ago Revival Gold Targets Underground Resource Growth With Drilling at Beartrack-Arnett Gold Project in Idaho
Published on 03/17/2026 at 17:58, 2 hours 12 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 15:30, 4 hours 39 minutes ago Original-Research: Desert Gold Ventures Inc. (von GBC AG): Buy
Published on 03/17/2026 at 15:19, 4 hours 50 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC
Published on 03/17/2026 at 07:00, 13 hours 10 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 2 hours ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 2 hours ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 2 hours ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
